

Ad hoc release

Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)

Biofrontera enters into finance contract with European Investmentbank

Leverkusen, Germany, May 19, 2017 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, and the European Investment Bank (EIB) have entered into an agreement today according to which the EIB will provide a loan of up to EUR 20 Million to the Biofrontera-Group. The loan is secured by a guarantee of the European Fund for Strategic Investments (EFSI). Up to EUR 10 Million will be available for disbursement from signature. Further EUR 10 Million may be drawn in two tranches within the next 24 months based on prior achievement of operational milestones. There is no obligation to call these tranches and no obligation to pay any commitment interest. Each tranche must be repaid five years after drawdown.

The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
e-mail: press@biofrontera.com